Home › Companies › VNDA

Vanda Pharmaceuticals Inc.

VNDA Rare disease Lead: Approved 9 Biotech Distilled articles ↓

Cardiovascular Dermatology GI/Hepatology Hematology Immunology Infectious Disease Neurology Ophthalmology Nucleic Acid Protein Small Molecule

Most recent annual filing: 2026-02-13

Pipeline (26 active programs)

Fanapt

iloperidone

HETLIOZ

tasimelteon

Small Molecule Target: MT1, MT2

Non-24-Hour Sleep-Wake Disorder Preclinical oral
Smith-Magenis Syndrome Approved oral
Jet Lag Disorder NDA Submitted oral
Insomnia NDA Submitted oral
Delayed Sleep Phase Disorder Phase 3 oral

PONVORY

ponesimod

Relapsing Forms of Multiple Sclerosis Approved oral
Psoriasis Phase 3 oral
Ulcerative Colitis Phase 3 oral

NEREUS

tradipitant

Small Molecule Target: GLP-1 receptor

Motion Sickness Approved oral Eli Lilly
Nausea and Vomiting Phase 3 oral Eli Lilly
Gastroparesis NDA Submitted oral Eli Lilly
Atopic Dermatitis Phase 3 oral Eli Lilly

Bysanti

milsaperidone

imsidolimab

Protein Target: IL-36R

Generalized Pustular Psoriasis NDA Submitted AnaptysBio

VTR-297

Small Molecule Target: HDAC

Onychomycosis Phase 1

VSJ-110

Small Molecule Target: CFTR

Dry Eye Disease Phase 1 University of California San Francisco

VPO-227

Small Molecule Target: CFTR

Cholera Phase 1 oral University of California San Francisco

VQW-765

Small Molecule Target: alpha-7 nicotinic acetylcholine receptor

Social Anxiety Disorder Phase 3 Novartis

VCA-894A

Nucleic Acid Target: IGHMBP2

Charcot-Marie-Tooth Disease Type 2S Phase 1 OliPass Corporation

VGT-1849A

Polycythemia Vera Preclinical OliPass Corporation

Biotech Distilled coverage (9)

2026-05-06 UPDATE: Vanda Pharmaceuticals (VNDA) — The Burn Rate Confession and the DTC Hail Mary
2026-03-21 UPDATE: Vanda’s $30 Million "Ethics" Play — Turning the Tradipitant Roadblock into a PR War 🔒 Paid
2026-03-07 UPDATE: Vanda’s (VNDA) Litigation Moat Makes History — The 40-Year FDA Streak is Broken 🔒 Paid
2026-02-28 UPDATE: Vanda Pharmaceuticals (VNDA) - The Narrative Machine Speeds Up 🔒 Paid
2026-02-21 UPDATE: Vanda Pharmaceuticals (VNDA) - The PDUFA Pop Arrives — Now Watch for the Anvil 🔒 Paid
2026-02-14 UPDATE: Vanda Pharmaceuticals (VNDA) - The Dilution Gap Confirmed — Vanda Drops a $200M Shelf 🔒 Paid
2026-02-11 UPDATE: Vanda Pharmaceuticals (VNDA) Expensive Victory Lap — NEREUS™ Approved, Cash Burn Accelerates 🔒 Paid
2026-01-10 UPDATE: Vanda vs. The FDA (Round Infinity) — The Jet Lag Denial 🔒 Paid
2025-12-31 FDA APPROVED Dec. 30, 2025 :: Vanda Pharmaceuticals (VNDA): Scientific Due Diligence for Tradipitant and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.